Table 2.

Association of CRY2 variants with NHL risk

Genotype	All			B-Cell			T-Cell
	Cases N	Controls N	OR† (95% CI)	Cases N	Controls N	OR† (95% CI)	Cases N	Controls N	OR† (95% CI)
rs11038689
A/A or A/G	408	495	-	326	495	-	29	495	-
G/G	33	17	2.34 (1.28-4.27)	26	17	2.35 (1.25-4.41)	3	17	2.69 (0.74-9.84)
P-value			0.006			0.008			0.135
rs11605924
A/A or A/C	327	365	-	263	365	-	25	365	-
C/C	114	151	0.82 (0.62-1.10)	89	151	0.79 (0.58-1.08)	8	151	0.78 (0.34-1.77)
P-value			0.182			0.142			0.550
rs2292912
C/C or C/G	418	489	-	334	489	-	32	489	-
G/G	23	29	1.00 (0.55-1.82)	18	29	1.03 (0.54-1.96)	1	29	0.48 (0.06-4.07)
P-value			0.990			0.938			0.502
rs7123390
G/G or G/A	396	491	-	315	491	-	29	491	-
A/A	41	21	2.40 (1.39-4.13)	34	21	2.54 (1.44-4.46)	3	21	2.11 (0.59-7.54)
P-value			0.002			0.001			0.253
rs1401417
G/G or G/C	409	503	-	331	503	-	28	503	-
C/C	34	14	2.97 (1.57-5.63)	26	14	2.87 (1.47-5.58)	4	14	4.64 (1.41-15.34)
P-value			0.001			0.002			0.012

^†Adjusted for age (continuous), race, and family history of cancer in 1st or 2nd degree relatives.